Walleye Capital
STRO icon

Walleye Capital’s Sutro Biopharma STRO Stock Holding History

Walleye Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,327
Closed -$314K – 5878
2023
Q4 		$314K Buy
+7,327
New +$233K ﹤0.01% 3340
2023
Q1 		– Sell
-1,806
Closed -$146K – 4345
2022
Q4 		$146K Sell
1,806
-17,366
-91% -$1.21M ﹤0.01% 2221
2022
Q3 		$1.06M Sell
19,172
-8,104
-30% -$480K 0.02% 927
2022
Q2 		$1.42M Buy
27,276
+20,915
+329% +$1.17M 0.04% 483
2022
Q1 		$523K Sell
6,361
-1,180
-16% -$112K 0.01% 993
2021
Q4 		$1.12M Buy
+7,541
New +$1.35M 0.03% 519
2018
Q3 		$201K Buy
+1,340
New +$202K 0.09% 219

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Walleye Capital's STRO Position: Q1 2024 in Review

Walleye Capital sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 7,327 shares — an estimated $314K sold.

Walleye Capital first reported a position in STRO in Q3 2018 and held it in 7 quarters. The position peaked at $1.42M in Q2 2022. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

  • Walleye Capital reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 7,327 Sutro Biopharma shares in Q1 2024, an estimated $314K.
  • Walleye Capital first reported a position in Sutro Biopharma in Q3 2018 and held it in 7 quarters.
  • Walleye Capital's Sutro Biopharma position peaked at $1.42M in Q2 2022.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.